J&J’s Janssen taps into Pipeline Therapeutics’ neuroscience asset for $50M upfront

Kyle LaHucik

Senior Reporter

Johnson & Johnson’s Janssen unit is delving into the muscarinic space with $50 million upfront for an oral Pipeline Therapeutics asset that will enter a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J’s Janssen taps into Pipeline Therapeutics’ neuroscience asset for $50M upfront

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Are programs with compounded GLP-1s safe for your population?

J&J’s Janssen taps in­to Pipeline Ther­a­peu­tics’ neu­ro­science as­set for $50M up­front

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

J&J’s Janssen taps into Pipeline Therapeutics’ neuroscience asset for $50M upfront

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Are programs with compounded GLP-1s safe for your population?